TTK Healthcare growth ratios

·OthersChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+7.0%+6.5%+3.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−24.8%−6.7%+19.1%
−34.3%+9.2%+30.9%
−19.6%+29.9%−90.2%
−19.6%+30.0%−90.2%
+3.7%+6.7%+2.6%
+4.7%+6.4%+5.0%
−431.9%+19.6%+81.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

TTKHLTCARE₹1,049.10

TTK Healthcare Limited

· Others
₹ CrorePeersDCMSHRIRAMBALMLAWRIEGODREJIND3MINDIAMcap ₹1,482 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+3.8+6.5+7.0—
EBITDA Growth—+19.1-6.7-24.8—
EBIT Growth—+30.9+9.2-34.3—
Net Income Growth—-90.2+29.9-19.6—
EPS Growth—-90.2+30.0-19.6—
Total Assets Growth—+2.6+6.7+3.7—
Total Equity Growth—+5.0+6.4+4.7—
Cash from Operations Growth—+81.0+19.6-431.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.